Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation

被引:9
|
作者
Akahoshi, Tomohiko [1 ,3 ]
Kaku, Noriyuki [1 ]
Shono, Yuji [1 ]
Yamamoto, Yuzo [1 ]
Takahashi, Keita [2 ]
Iyonaga, Takeshi [1 ]
Momii, Kenta [1 ]
Nishihara, Masaaki [1 ]
Maki, Jun [2 ]
Tokuda, Kentaro [2 ]
Yamaura, Ken [2 ]
机构
[1] Kyushu Univ Hosp, Emergency & Crit Care Ctr, Fukuoka, Japan
[2] Kyushu Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med Sci, Fukuoka, Japan
[3] Kyushu Univ Hosp, Emergency & Crit Care Ctr, 3 1 1 Maidashi, Higashi ku, Fukuoka 8128582, Japan
关键词
disseminated intravascular coagulation; sepsis; antithrombin activity; recombinant antithrombin gamma; CRITICALLY-ILL PATIENTS; DIAGNOSTIC-CRITERIA; EFFICACY; SAFETY; SUPPLEMENTATION; MULTICENTER; THROMBOMODULIN; HEPARIN;
D O I
10.1177/10760296221135790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant antithrombin gamma (rAT) is reported as an effective drug for patients with disseminated intravascular coagulation (DIC) in Japan. As the appropriate dose and targeted AT activity remain unknown, this study aimed to determine these aspects for sepsis-induced DIC. Thirty-one patients with septic shock and DIC with AT levels <70% were treated with rAT between May 2018 and December 2020. The recovery rates from DIC were 32.2% and 63.3% on day 3 and 5 post administration, respectively. Recovery and survival rates were significantly higher in patients who achieved AT activity >= 70% or 80% on day 3 post administration. Receiver operating characteristic curve analysis revealed that the cutoff values of post-treatment AT activity on day 3 for 28-day survival and 5-day recovery from DIC were 79.5% and 81.5%, respectively. Patients who did not achieve AT activity >= 80% on day 3 presented a lower base level of AT activity and lower dose supplementation. Our results suggest that targeted AT activity should be at least 70%, and ideally 80%, and sufficient doses to maintain this activity are required to achieve better outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy
    Iba, Toshiaki
    Umemura, Yutaka
    Watanabe, Eizo
    Wada, Takeshi
    Hayashida, Kei
    Kushimoto, Shigeki
    ACUTE MEDICINE & SURGERY, 2019, 6 (03): : 223 - 232
  • [22] Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis
    Nakahara, Kazunari
    Okuse, Chiaki
    Adachi, Seitaro
    Suetani, Keigo
    Kitagawa, Sarika
    Okano, Miki
    Michikawa, Yosuke
    Takagi, Rei
    Shigefuku, Ryuta
    Itoh, Fumio
    GUT AND LIVER, 2013, 7 (03) : 363 - 370
  • [23] Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin
    Iba, Toshiaki
    Arakawa, Makoto
    Levy, Jerrold H.
    Yamakawa, Kazuma
    Koami, Hiroyuki
    Hifumi, Toru
    Sato, Koichi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (07) : 1020 - 1026
  • [24] Effects of Antithrombin on Persistent Inflammation, Immunosuppression, and Catabolism Syndrome among Patients with Sepsis-Induced Disseminated Intravascular Coagulation
    Kanda, Naoki
    Ohbe, Hiroyuki
    Nakamura, Kensuke
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
  • [25] Impact of non-anticoagulant therapy on patients with sepsis-induced disseminated intravascular coagulation: A multicenter, case-control study
    Kudo, Daisuke
    Hayakawa, Mineji
    Ono, Kota
    Yamakawa, Kazuma
    THROMBOSIS RESEARCH, 2018, 163 : 22 - 29
  • [26] Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
    Yamakawa, Kazuma
    Ogura, Hiroshi
    Fujimi, Satoshi
    Morikawa, Miki
    Ogawa, Yoshihito
    Mohri, Tomoyoshi
    Nakamori, Yasushi
    Inoue, Yoshiaki
    Kuwagata, Yasuyuki
    Tanaka, Hiroshi
    Hamasaki, Toshimitsu
    Shimazu, Takeshi
    INTENSIVE CARE MEDICINE, 2013, 39 (04) : 644 - 652
  • [27] Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation A multicentre retrospective study
    Hayakawa, Mineji
    Yamakawa, Kazuma
    Saito, Shinjiro
    Uchino, Shigehiko
    Kudo, Daisuke
    Iizuka, Yusuke
    Sanui, Masamitsu
    Takimoto, Kohei
    Mayumi, Toshihiko
    Ono, Kota
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (06) : 1157 - 1166
  • [28] Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation
    Toshiaki Iba
    Akiyoshi Hagiwara
    Daizoh Saitoh
    Hideaki Anan
    Yutaka Ueki
    Koichi Sato
    Satoshi Gando
    Annals of Intensive Care, 7
  • [29] Age Is Associated With the Efficacy of Anticoagulant Therapies Against Sepsis-Induced Disseminated Intravascular Coagulation
    Takahashi, Kyosuke
    Umemura, Yutaka
    Yamakawa, Kazuma
    Ogura, Hiroshi
    Shimazu, Takeshi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [30] An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome
    Endo, Shigeatsu
    Shimazaki, Ryutaro
    JOURNAL OF INTENSIVE CARE, 2018, 6